Verona Pharma plc - Ordinary Shares, nominal value 0.05 GBP per share (VRNA) Institutional Ownership

13F Institutional Holders and Ownership History from Q2 2017 to Q4 2025

Type / Class
Equity / Ordinary Shares, nominal value 0.05 GBP per share
Symbol
VRNA
Shares outstanding
84,213,667
Price per share
$106.91
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
80,398,842
Total reported value
$8,578,750,126
% of total 13F portfolios
0.05%
Share change
+4,674,747
Value change
+$837,023,417
Number of holders
243
Price from insider filings
$106.91
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Verona Pharma plc - Ordinary Shares, nominal value 0.05 GBP per share (VRNA) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Growth Equity Opportunities Fund IV, LLC 5% $2,139,209,824 32,679,649 Scott D. Sandell 16 Jan 2025
MAVERICK CAPITAL LTD 3.8% $1,638,341,259 25,028,128 Maverick Capital, Ltd. 31 Dec 2024
JANUS HENDERSON GROUP PLC 1.2% -86% $107,837,284 -$546,765,073 1,010,564 -84% JANUS HENDERSON GROUP PLC 30 Sep 2025
RA CAPITAL MANAGEMENT, L.P. 0.7% -91% $62,198,806 -$567,585,398 593,670 -90% RA Capital Management, L.P. 30 Jun 2025

As of 30 Sep 2025, 243 institutional investors reported holding 80,398,842 shares of Verona Pharma plc - Ordinary Shares, nominal value 0.05 GBP per share (VRNA). This represents 95% of the company’s total 84,213,667 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Verona Pharma plc - Ordinary Shares, nominal value 0.05 GBP per share (VRNA) together control 66% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Pentwater Capital Management LP 6.3% 5,300,000 5.1% $565,563,000
OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) 5.1% 4,283,462 28% $457,088,230
HBK INVESTMENTS L P 5.1% 4,263,576 6.7% $454,966,195
BlackRock, Inc. 4.5% 3,826,710 +1013% 0.01% $408,348,224
FIL Ltd 4.1% 3,488,500 0.29% $372,257,835
Frazier Life Sciences Management, L.P. 4% 3,383,950 0% 11% $361,101,305
Davidson Kempner Capital Management LP 3.9% 3,271,623 6.5% $349,114,890
GLAZER CAPITAL, LLC 3.8% 3,205,878 11% $342,099,000
NEA Management Company, LLC 2.7% 2,252,994 -0.45% 13% $240,416,990
GOLDMAN SACHS GROUP INC 2.3% 1,935,278 -26% 0.03% $206,513,516
Balyasny Asset Management L.P. 2.2% 1,863,426 +214% 0.4% $198,846,188
MILLENNIUM MANAGEMENT LLC 2.1% 1,796,738 +376% 0.15% $191,729,912
SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC 2.1% 1,785,407 -17% 6.2% $190,520,781
MORGAN STANLEY 1.9% 1,575,904 +764% 0.01% $168,164,782
WHITEBOX ADVISORS LLC 1.9% 1,566,501 3.2% $167,161,322
JPMORGAN CHASE & CO 1.7% 1,414,770 +297% 0.01% $150,970,107
BARCLAYS PLC 1.7% 1,393,716 +1160% 0.06% $148,723,434
Vivo Capital, LLC 1.7% 1,393,432 0% 12% $148,693,129
SYQUANT CAPITAL SAS 1.4% 1,208,312 37% $128,939,000
ALPINE ASSOCIATES MANAGEMENT INC. 1.4% 1,157,050 7.5% $123,468,806
JANUS HENDERSON GROUP PLC 1.2% 1,010,564 -84% 0.05% $107,839,626
Duquesne Family Office LLC 1.2% 1,002,080 0% 2.7% $106,932,000
Polar Asset Management Partners Inc. 1.2% 970,000 +8262% 2.1% $103,508,700
KRYGER CAPITAL Ltd 1.1% 962,341 12% $102,691,408
First Trust Capital Management L.P. 1.1% 909,123 6.3% $97,012,515

Institutional Holders of Verona Pharma plc - Ordinary Shares, nominal value 0.05 GBP per share (VRNA) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 0 $0 -$166,828,130 $106.91 0
2025 Q3 80,398,842 $8,578,750,126 +$837,023,417 $106.71 243
2025 Q2 75,959,176 $7,178,711,698 +$377,068,942 $94.58 291
2025 Q1 72,226,156 $4,575,336,285 +$289,861,737 $63.49 258
2024 Q4 68,611,559 $3,186,422,108 +$45,832,094 $46.44 192
2024 Q3 67,675,281 $1,950,276,918 +$158,137,487 $28.77 149
2024 Q2 66,174,147 $956,862,178 -$15,389,539 $14.46 125
2024 Q1 66,961,392 $1,084,932,320 -$17,301,242 $16.09 113
2023 Q4 67,202,638 $1,345,422,422 +$16,673,493 $19.88 116
2023 Q3 64,968,404 $1,066,709,124 +$34,858,183 $16.30 101
2023 Q2 62,584,885 $1,332,969,384 +$50,184,333 $21.14 104
2023 Q1 60,335,461 $1,211,517,782 +$167,801,714 $20.08 93
2022 Q4 50,105,712 $1,309,183,295 +$112,055,574 $26.13 88
2022 Q3 51,774,348 $528,758,643 +$182,949,663 $10.22 65
2022 Q2 34,799,135 $145,683,724 -$8,606,491 $4.19 36
2022 Q1 36,443,868 $181,735,244 -$2,536,945 $4.99 38
2021 Q4 36,936,117 $248,013,599 +$379,094 $6.72 41
2021 Q3 37,018,796 $202,742,194 +$753,340 $5.48 38
2021 Q2 36,699,886 $239,939,874 +$947,435 $6.54 35
2021 Q1 36,531,198 $305,130,909 +$6,927,568 $8.36 36
2020 Q4 35,736,138 $246,007,905 +$8,102,449 $7.00 34
2020 Q3 34,077,017 $212,640,000 +$168,041,172 $6.24 28
2020 Q2 7,173,525 $33,588,000 +$911,545 $4.68 18
2020 Q1 6,984,029 $28,790,000 +$4,644,284 $4.12 14
2019 Q4 5,849,679 $33,680,000 +$46,378 $5.75 13
2019 Q3 5,862,079 $26,791,000 -$7,634,329 $4.57 12
2019 Q2 7,368,227 $37,584,000 -$77,763 $5.10 16
2019 Q1 7,381,315 $47,545,000 -$1,633,811 $6.50 17
2018 Q4 8,407,168 $78,583,000 -$2,815,272 $9.05 17
2018 Q3 7,376,882 $92,275,000 +$11,046,083 $12.51 14
2018 Q2 6,490,956 $71,091,000 -$1,254,345 $13.66 13
2018 Q1 6,582,135 $131,642,000 -$1,915,281 $20.00 14
2017 Q4 6,677,932 $79,300,000 +$6,207,670 $11.87 10
2017 Q3 5,279,998 $81,047,000 +$20,684,812 $15.35 9
2017 Q2 3,954,155 $46,085,000 +$46,085,000 $11.66 9